Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2025-08-26 | Reverse | 1:4 |
| 2021-03-17 | Reverse | 1:16 |
Chemomab Therapeutics Ltd., a Tel Aviv-based clinical-stage biotech founded in 2011, develops therapeutics like its lead candidate CM-101, a monoclonal antibody targeting chemokine CCL24 for inflammation and fibrosis-related diseases such as PSC a...

Nebokitug is Chemomab's lead monoclonal antibody targeting CCL24 to treat rare fibro-inflammatory diseases, primarily Primary Sclerosing Cholangitis (PSC).
Overall rating: C
| PEER | PRICE | |
|---|---|---|
KZIA | $13.58 | COMPARE |
BIVI | $2.16 | COMPARE |
GLMD | $4.17 | COMPARE |
INM | $1.38 | COMPARE |
ELAB | $5.31 | COMPARE |
XRTX | $2.34 | COMPARE |
CERO | $0.01 | COMPARE |
OCEA | $0.00 | COMPARE |